CLOV Clover Health
- 0.655
- -0.025-3.69%
Clover Health News
Clover Health to Report First Quarter 2024 Financial Results on May 7, 2024
FRANKLIN, Tenn., April 23, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will report first quarter 2024 financial results
Express News | Clover Health Appoints Healthcare Technology Veteran Peter Kuipers as Chief Financial Officer
Clover Health Investments, Corp.'s (NASDAQ:CLOV) Stock Price Dropped 15% Last Week; Individual Investors Would Not Be Happy
Key Insights The considerable ownership by individual investors in Clover Health Investments indicates that they collectively have a greater say in management and business strategy 40% of the busine
Fitch Flags Medicare Utilization Trends Ahead of Managed Care Earnings
Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort
-- Bivalent SCB-1019 significantly boosted RSV-A and RSV-B neutralization titers to approximately 6,600 IU/mL (6.4-fold increase) and approximately 46,000 IU/mL (12-fold increase), respectively -- --
On April 2, Clover Health Investments Corp Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
On April 2, Clover Health Investments Corp Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Clover Health Provides Notice Associated With Previously Disclosed Settlement of Shareholder Derivative Actions
FRANKLIN, Tenn., April 04, 2024 (GLOBE NEWSWIRE) -- As previously disclosed, most recently in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and in its Quarterly Report on Form 10-Q for the
Managed Care Stocks Drop After Medicare Rate Decision
HHS Says In 2025, All People With Medicare Part D Will Benefit From A $2,000 Cap On Annual Out-Of-Pocket Prescription Drug Costs
HHS Says In 2025, All People With Medicare Part D Will Benefit From A $2,000 Cap On Annual Out-Of-Pocket Prescription Drug Costs
Medicare Expands Coverage for Weight Loss Drugs
Cautious Optimism on Clover Health's Performance With Concerns on Long-Term Profitability
Clover Health Launches New Clinical Program In Partnership With Quartet Health To Address Serious Mental Illness
Clover Health ("Clover" or the "Company") announced a partnership with Quartet Health, a value-based behavioral health care enablement and delivery company, to increase the support and resources provi
Clover Health Launches New Clinical Program in Partnership With Quartet Health to Address Serious Mental Illness
Clover Health(CLOV.US) Director Buys US$109.96K in Common Stocks
$Clover Health(CLOV.US)$ Director Loengard Anna U purchased 150.63K shares of Common Stocks on Mar 14, 2024 at an average price of $0.73 for a total value of $109.96K.Source: Announcement What is stat
Downgrade: Here's How Analysts See Clover Health Investments, Corp. (NASDAQ:CLOV) Performing In The Near Term
The latest analyst coverage could presage a bad day for Clover Health Investments, Corp. (NASDAQ:CLOV), with the analysts making across-the-board cuts to their statutory estimates that might leave sha
Peering Into Clover Health Investments's Recent Short Interest
Clover Health Investments's (NYSE:CLOV) short percent of float has risen 6.6% since its last report. The company recently reported that it has 29.52 million shares sold short, which is 7.43% of all re
Clover Health Investments Full Year 2023 Earnings: Beats Expectations
Q4 2023 Clover Health Investments Corp Earnings Call
Clover Health Investments: A Strong Buy on Rising Revenues, Improved Cost Management, and a Path to Profitability
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday. Shares of The Beauty Health Company (NASDAQ:SKIN) rose sharply in today's pre-market tra
Analysis
Price Target
No Data
